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Invited Commentary for British Journal of Dermatology 
A changing treatment paradigm: The role of palliative care in metastatic melanoma 
Palliative care has been identified as an important component of the cancer trajectory with an increasing 
number of studies identifying the benefits of early referral.1,2 Within this framework, the alleviation of 
symptoms, communication around health care goals, and support for both patients and families 
throughout the course of the illness trajectory is the focus. Indeed studies point to a clear positive 
relationship between early integration of palliative care and improvements in quality of life. Better 
outcomes for patients and carers are evident with improvements in symptom management and patient 
satisfaction, decreases in carer burden, and reduced use of futile interventions.3 The timely adoption of a 
palliative approach to care, or an appropriate referral to specialist palliative care, plays an essential role in 
achieving these outcomes. 
 
Despite these identified benefits there is variability in access to palliative care with referrals occurring late 
in the disease trajectory. This is particularly evident in the current context of metastatic melanoma. While 
the treatment of patients with metastatic melanoma remained a major therapeutic challenge for decades, 
in the last three to four years innovative treatments in the form of immune and targeted therapies have 
demonstrated increased overall survival.4,5 This is welcome news. However, the ongoing uncertainty of the 
disease trajectory and a lack of clarity around the concept of palliative care, add complexity to the already 
difficult interface between oncology and palliative services.6  
 
This concern is examined in the article by Gallais Sérezal et al.7 in this issue of the BJD where the prevalence 
of aggressive treatments near the end of life for hospitalised patients with metastatic melanoma is 
highlighted. The use of chemotherapy, radiation therapy, blood transfusions, ICU admission and long 
hospital stays were common during the last month of life with one in four patients dying without any 
identification of palliative care needs. It is recognised that not all patients who die require a referral to 
specialist palliative care. However, identification of palliative needs is essential for improvements in quality 
of life as patients approach end of life. Indeed, a significant proportion of palliative care can be provided by 
the treating cancer care team and consultation with a specialist palliative team is reserved for more 
complex issues.8 
 
The study addresses patients who died in hospital facilities which may indicate more aggressive treatment 
near the end of life compared with patients who died in community settings. It highlights the need for 
practice change. Innovations in life-extending treatments create an opportunity for more considered 
discussions around end-of-life care for patients with metastatic melanoma in hospital. Importantly, basic 
levels of competence in providing a standardised and evidence based palliative approach to care by all 
hospital based clinicians may enable these discussions to occur in a timely manner. This may result in a 
reduction in inappropriate aggressive treatments during the last months of life and promote optimal use of 
specialist palliative care services.  
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